Why the study?
Conventional anti-platelet agents have limited efficacy in secondary stroke prevention under high shear stress with elevated VWF, prompting characterization of the anti-VWF aptamer BT200 in blood from patients with large artery atherosclerosis stroke.
Does BT200 inhibit VWF activity and platelet function in blood samples from patients with large artery atherosclerosis stroke?
Population
33 patients with acute stroke or transient ischemic attack
Comparison
Concentration-dependent effects of BT200 on blood samples
Design
Ex vivo laboratory study
Authors
Loading...
BT200 inhibits VWF activity in acute stroke blood; leaves open efficacy for secondary prevention in prospective trials.
Does BT200 inhibit VWF activity and platelet function in blood samples from patients with large artery atherosclerosis stroke?
The anti-VWF aptamer BT200 effectively inhibits VWF activity and platelet function in ex vivo blood samples from stroke patients, highlighting its potential as a novel antiplatelet agent for secondary stroke prevention.
Kovacevic et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: